MCMindy Clyne

Mindy Clyne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mindy Clyne has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Muin J. Khoury

    Office of Public Health Genomics, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA

    7 shared publications
  • Muin J. Khoury

    Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA

    6 shared publications
  • Marta Gwinn

    1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA

    4 shared publications
  • Anja Wulf

    Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    3 shared publications
  • Katherine Kolor

    Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    3 shared publications
  • Tram Kim Lam

    National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland

    3 shared publications

Latest Publications

  • Dissemination and Implementation Research at the National Cancer Institute: A Review of Funded Studies (2006–2019) and Opportunities to Advance the Field

    by Gila Neta, Mindy Clyne, David A. Chambers

    Background: To ensure investment in cancer research reaches populations who can benefit, the NCI has funded implementation science grants since the Dissemination and Implementation Research in Health (DIRH) funding opportunities launched in 2006. We analyzed NCI-funded DIRH grants to provide a snapshot of implementation science conducted across the cancer care continuum and highlight areas ripe for exploration. Methods: NCI-funded DIRH grants between fiscal years 2006 and 2019 were identified using the iSearch database. Two coders classified each grant by topic, populations studied, intervention and setting characteristics, strategies tested, study designs and methods used, and outcomes measured. Results: Seventy-one grants were awarded addressing cancer prevention (n = 33), screening (n = 33), diagnosis (n = 4), treatment (n = 9), and/or survivorship (n = 11). Colorectal (n = 20), breast (n = 15), and cervical (n = 11) were the most studied cancers. Most grants focused on delivery of guidelines (n = 36) or behavioral change interventions (n = 18) in health care settings (n = 47), studying implementation processes (n = 37) and/or testing implementation strategies (n = 43) using experimental (n = 35) and quasi-experimental (n = 6) designs. Few studied sustainability (n = 7), scale-up (n = 2), deimplementation (n = 4), measure development (n = 6), or policy-level implementation (n = 6). Conclusions: Current funding suggests researchers are studying implementation of cancer control interventions across the care continuum. However, research gaps remain in strategies for sustainability, scale-up, and deimplementation. More emphasis is needed on cancer treatment and survivorship. Additional focus on policy implementation and measure development is warranted. Impact: Understanding the breadth of NCI-funded implementation science can inform future efforts to build the knowledge base on how to improve dissemination and implementation of evidence in cancer control.


  • A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer

    by Melissa Rotunno, Rolando Barajas, Mindy Clyne, Elise Hoover, Naoko I. Simonds, Tram Kim Lam, Leah E. Mechanic, Alisa M. Goldstein, Elizabeth M. Gillanders

    The application of next-generation sequencing (NGS) technologies in cancer research has accelerated the discovery of somatic mutations; however, progress in the identification of germline variation associated with cancer risk is less clear. We conducted a systematic literature review of cancer genetic susceptibility studies that used NGS technologies at an exome/genome-wide scale to obtain a fuller understanding of the research landscape to date and to inform future studies. The variability across studies on methodologies and reporting was considerable. Most studies sequenced few high-risk (mainly European) families, used a candidate analysis approach, and identified potential cancer-related germline variants or genes in a small fraction of the sequenced cancer cases. This review highlights the importance of establishing consensus on standards for the application and reporting of variants filtering strategies. It also describes the progress in the identification of cancer-related germline variation to date. These findings point to the untapped potential in conducting studies with appropriately sized and racially diverse families and populations, combining results across studies and expanding beyond a candidate analysis approach to advance the discovery of genetic variation that accounts for the unexplained cancer heritability.


  • Open Access

    Tracking human genes along the translational continuum

    by Kyubum Lee, Mindy Clyne, Wei Yu, Zhiyong Lu, Muin J. Khoury

    Understanding the drivers of research on human genes is a critical component to success of translation efforts of genomics into medicine and public health. Using publicly available curated online databases we sought to identify specific genes that are featured in translational genetic research in comparison to all genomics research publications. Articles in the CDC’s Public Health Genomics and Precision Health Knowledge Base were stratified into studies that have moved beyond basic research to population and clinical epidemiologic studies (T1: clinical and population human genome epidemiology research), and studies that evaluate, implement, and assess impact of genes in clinical and public health areas (T2+: beyond bench to bedside). We examined gene counts and numbers of publications within these phases of translation in comparison to all genes from Medline. We are able to highlight those genes that are moving from basic research to clinical and public health translational research, namely in cancer and a few genetic diseases with high penetrance and clinical actionability. Identifying human genes of translational value is an important step towards determining an evidence-based trajectory of the human genome in clinical and public health practice over time.


  • Abstract 1600: A literature review of whole exome and genome sequencing population studies for identifying novel germline mutations in relation to cancer risk

    by Rolando Barajas, Elise Hoover, Mindy Clyne, Tram Lam, Leah Mechanic, Alisa Goldstein, Elizabeth Gillanders, Melissa Rotunno

    The application of Next Generation Sequencing (NGS) technologies in cancer research has accelerated the discovery of somatic mutations; however, it has not mirrored the same progress in the identification of cancer associated germline variation. With the goal to inform future studies on commonly used methods and their degree of success and limitations in identifying germline variants associated with cancer, we performed a review of the English literature for genome-wide germline sequencing studies aimed at identifying new cancer susceptibility genes or variants. A key words search in 2005-April 2017 PubMed yielded 7,349 articles which were checked against the following exclusion criteria: non-cancer (1852), somatic mutations (1764), methods (905), reviews (872), non-human (735), expression (272), targeted sequencing (224), commentaries (170), epigenetic (135), non-English (89), functional (85), clinical studies (51), others (44). The remaining 151 publications were examined in-depth and coded in an Access database according to ~60 fields, capturing information on: publication (journal, year, author, title, abstract), study design (goal; cancer type; population and ethnicity; discovery, technical validation, and replication phases; numbers and characteristics of cases, controls, families used in each phase), sequencing technique (center, technology, coverage, reads aligner, variants caller, QCs), data analysis (variants annotation, candidate genes, filtering strategy, association test), in silico and experimental functional assessment, and key conclusions (main results, challenges, next steps). The discovery phase of the examined papers was largely based on familial cases (77%), exome/genome sequencing of one single family (31%), and restricted to the analysis of candidate genes lists. The distribution of ethnicity for the sequenced cancer patients was 38% European, 11% Asian, 10% African, 5% multi-ethnic, 4% African American, 3% Latino/Hispanic, 3% Middle Eastern, 1% Jewish, and 25% unreported. Breast, prostate, colorectal, and lung cancer represented ~40% of the assessed articles, and the remaining 60% a diverse group of rare cancer types. Most studies (~80%) included a technical validation phase, but without clear success rate. Only 60% of studies included a replication phase in an independent population. Although most studies (~80%) described the identification of multiple germline variants and genes thought to have a role in cancer susceptibility, the supporting evidence was often disparate or not clearly stated. Our findings underscore the importance of establishing standards for reporting filtering strategies and rational for variant identification. We identified untapped potentials in the utilization of more/larger families, the harmonization of results across studies, and the expansion beyond candidate genes. Citation Format: Rolando Barajas, Elise Hoover, Mindy Clyne, Tram Lam, Leah Mechanic, Alisa Goldstein, Elizabeth Gillanders, Melissa Rotunno. A literature review of whole exome and genome sequencing population studies for identifying novel germline mutations in relation to cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1600.

  • Open Access

    Using deep learning to identify translational research in genomic medicine beyond bench to bedside

    by Yi-Yu Hsu, Mindy Clyne, Chih-Hsuan Wei, Muin J Khoury, Zhiyong Lu

    Tracking scientific research publications on the evaluation, utility and implementation of genomic applications is critical for the translation of basic research to impact clinical and population health. In this work, we utilize state-of-the-art machine learning approaches to identify translational research in genomics beyond bench to bedside from the biomedical literature. We apply the convolutional neural networks (CNNs) and support vector machines (SVMs) to the bench/bedside article classification on the weekly manual annotation data of the Public Health Genomics Knowledge Base database. Both classifiers employ salient features to determine the probability of curation-eligible publications, which can effectively reduce the workload of manual triage and curation process. We applied the CNNs and SVMs to an independent test set (n = 400), and the models achieved the F-measure of 0.80 and 0.74, respectively. We further tested the CNNs, which perform better results, on the routine annotation pipeline for 2 weeks and significantly reduced the effort and retrieved more appropriate research articles. Our approaches provide direct insight into the automated curation of genomic translational research beyond bench to bedside. The machine learning classifiers are found to be helpful for annotators to enhance the efficiency of manual curation.


  • Using Precision Medicine to Improve Health and Healthcare

    by Mindy Clyne, Amy Kennedy, Muin J. Khoury

    Implementation science can be incorporated within genomics precision medicine research across the cancer care continuum. Cancer is at the forefront of precision medicine. To move the field forward, the use of implementation science frameworks, theories, models, strategies, and outcome measures is essential so that we can consistently explore how precision medicine discoveries are optimally integrated into care delivery systems. Learning health care systems are model systems for adoption, uptake, and sustainability of precision medicine throughout the cancer care continuum, with both systematic processes in place for research to inform practice, and capacity for a multilevel research agenda, including the utilization of implementation strategies across and among multiple levels. This chapter explores precision medicine across the cancer care continuum and describes implementation science challenges and opportunities.

  • Proposed outcomes measures for state public health genomic programs

    by Debra Lochner Doyle, Mindy Clyne, Juan L. Rodriguez, Deborah L. Cragun, Laura Senier, Georgia Hurst, Kee Chan, David A. Chambers


  • Open Access

    From public health genomics to precision public health: a 20-year journey

    by Muin J. Khoury, M. Scott Bowen, Mindy Clyne, W. David Dotson, Marta L. Gwinn, Ridgely Fisk Green, Katherine Kolor, Juan L. Rodriguez, Anja Wulf, Wei Yu


  • Trends in published meta-analyses in cancer research, 2008–2013

    by Ximena V. Qadir, Mindy Clyne, Tram Kim Lam, Muin J. Khoury, Sheri D. Schully

    In order to capture trends in the contribution of epidemiology to cancer research, we describe an online meta-analysis database resource for cancer clinical and population research and illustrate trends and descriptive detail of cancer meta-analyses from 2008 through 2013. A total of 4,686 cancer meta-analyses met our inclusion criteria. During this 6-year period, a fivefold increase was observed in the yearly number of meta-analyses. Fifty-six percent of meta-analyses concerned observational studies, mostly of cancer risk, more than half of which were genetic studies. The major cancer sites were breast, colorectal, and digestive. This online database for Cancer Genomics and Epidemiology Navigator will be continuously updated to allow investigators to quickly navigate the meta-analyses emerging from cancer epidemiology studies and cancer clinical trials.